{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:43:58Z","timestamp":1787240638425,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.jad.2005.02.017","type":"journal-article","created":{"date-parts":[[2005,5,15]],"date-time":"2005-05-15T01:27:36Z","timestamp":1116120456000},"page":"115-119","source":"Crossref","is-referenced-by-count":25,"title":["Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression"],"prefix":"10.1016","volume":"87","author":[{"given":"David L.","family":"Dunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah N.","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Kajdasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Detke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jad.2005.02.017_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0165-0327(00)00203-2","article-title":"Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders","volume":"59","author":"Akiskal","year":"2000","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2005.02.017_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0165-0327(99)00149-4","article-title":"Venlafaxine monotherapy in women with bipolar II and unipolar major depression","volume":"59","author":"Amsterdam","year":"2000","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2005.02.017_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00004714-199812000-00003","article-title":"Efficacy and safety of fluoxetine in treating bipolar II major depressive episode","volume":"18","author":"Amsterdam","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2\u20133","key":"10.1016\/j.jad.2005.02.017_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000284227","article-title":"Switch from depression to mania\u2014a record study over decades between 1920 and 1982","volume":"18","author":"Angst","year":"1985","journal-title":"Psychopathology"},{"issue":"1","key":"10.1016\/j.jad.2005.02.017_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-0327(97)00082-7","article-title":"Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice","volume":"46","author":"Benazzi","year":"1997","journal-title":"J. Affect. Disord."},{"issue":"1\u20133","key":"10.1016\/j.jad.2005.02.017_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0165-0327(01)00444-X","article-title":"Delineating bipolar II mixed states in the Ravenna\u2013San Diego collaborative study: the relative prevalence and diagnostic significance of hypomanic features during major depressive episodes","volume":"67","author":"Benazzi","year":"2001","journal-title":"J. Affect. Disord."},{"issue":"1\u20132","key":"10.1016\/j.jad.2005.02.017_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-0327(02)00327-0","article-title":"Refining the evaluation of bipolar II: beyond the strict SCID-CV guidelines for hypomania","volume":"73","author":"Benazzi","year":"2003","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.jad.2005.02.017_bib8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2005.02.017_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.1399-5618.2003.00084.x","article-title":"A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V","volume":"6","author":"Chun","year":"2004","journal-title":"Bipolar Disord."},{"issue":"Suppl. 2","key":"10.1016\/j.jad.2005.02.017_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00004850-199503002-00004","article-title":"Safety and tolerance profile of venlafaxine","volume":"10","author":"Danjou","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.jad.2005.02.017_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004714-199910000-00003","article-title":"Venlafaxine in treatment-resistant major depressin: a Canadian multicenter, open-label trial","volume":"19","author":"De Montigny","year":"1999","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2005.02.017_bib12","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4088\/JCP.v63n0407","article-title":"Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial","volume":"63","author":"Detke","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2005.02.017_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3956(02)00060-2","article-title":"Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression","volume":"36","author":"Detke","year":"2002","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.jad.2005.02.017_bib14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v58n1203","article-title":"Venlafaxine in dysthymic disorder","volume":"58","author":"Dunner","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2005.02.017_bib15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4088\/JCP.v61n1013","article-title":"Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study","volume":"61","author":"Ghaemi","year":"2000","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2005.02.017_bib16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4088\/JCP.v62n0406","article-title":"Antidepressant-induced mania in bipolar patients: identification of risk factors","volume":"62","author":"Henry","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 14","key":"10.1016\/j.jad.2005.02.017_bib17","first-page":"5","article-title":"Bipolar spectrum disorder: improving its recognition and diagnosis","volume":"62","author":"Hirschfeld","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2005.02.017_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00004714-199612000-00003","article-title":"Induction of mania with serotonin reuptake inhibitors","volume":"16","author":"Howland","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.jad.2005.02.017_bib19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1176\/ajp.145.7.804","article-title":"Possible role of antidepressants in precipitating mania and hypomania in recurrent depression","volume":"145","author":"Kupfer","year":"1988","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2005.02.017_bib20","first-page":"106","article-title":"Duloxetine for the treatment of major depressive disorder","volume":"36","author":"Nemeroff","year":"2002","journal-title":"Psychopharmacol. Bull."},{"issue":"4","key":"10.1016\/j.jad.2005.02.017_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0447.1993.tb03370.x","article-title":"A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder","volume":"87","author":"Nielsen","year":"1993","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.jad.2005.02.017_bib22","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1192\/bjp.164.4.549","article-title":"Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants","volume":"164","author":"Peet","year":"1994","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2005.02.017_bib23","series-title":"Physician's Desk Reference","author":"Physician's Desk Reference","year":"2002"},{"issue":"1","key":"10.1016\/j.jad.2005.02.017_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-198502000-00002","article-title":"Adverse reactions to monoamine oxidase inhibitors: Part II. Treatment correlates and clinical management","volume":"5","author":"Rabkin","year":"1985","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 20","key":"10.1016\/j.jad.2005.02.017_bib25","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.jad.2005.02.017_bib26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(97)01393-9","article-title":"Pharmacological profile of antidepressants and related compounds at human monoamine transporters","volume":"340","author":"Tatsumi","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jad.2005.02.017_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-0348-8183-8_5","article-title":"Dual serotonin and noradrenaline uptake inhibitor class of anti-depressants\u2014potential for greater efficacy or just hype?","volume":"58","author":"Wong","year":"2002","journal-title":"Prog. Drug Res."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032705000741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032705000741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T08:53:37Z","timestamp":1548492817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032705000741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0165032705000741"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2005.02.017","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}